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Summary 
Cytokines have been shown to be powerful regulators of the immune response.  In this study, 
we analyze the effect that the newly recognized cytokine interleukin  (IL)-15 has on prolifera- 
tion and cytokine induction using peripheral blood mononuclear cells  (PBMCs)  and purified 
CD4 §  T  cells  from patients  infected with human immunodeficiency virus  (HIV) who are at 
various stages in their disease. We observed that IL-15 enhances the proliferative response in a 
dose-dependent  manner from PBMCs of HIV-infected individuals  when stimulated by poly- 
clonal mitogen,  tetanus  toxoid,  or HIV-specific antigen.  The  effects of exogenous IL-15 are 
substantially diminished by adding a neutralizing antibody to the [3 chain of the IL-2 receptor. 
Moreover, the ability of IL-15 to increase proliferation is enhanced by the presence of endoge- 
nous IL-2 produced in the  cultures.  The effect that exogenous IL-15 had on IL-2, IL-4, and 
interferon (IFN)-y induction from PBMC's or CD4 + T  cells in response to mitogen or tetanus 
toxoid was also examined. This was compared to the effect that exogenous IL-2 and IL-12 had 
under the same conditions. Addition of IL-2 or IL-15 to short-term in vitro cultures of either 
PBMCs or CD4 + T  cells had little effect on IL-2, IL-4, or IFN-~/production. By contrast, IL- 
12  caused substantial  enhancement  of both IL-2 and  IFN-',/ production from these  cultures. 
The role that endogenous cytokines have on IFN-y induction was also studied. Addition of a 
neutralizing antibody to the cx chain of the  IL-2 receptor or IL-12 to antigen stimulated  cul- 
tures caused a striking decrease in IFN-y production. Neutralization of endogenous IL-15 also 
resulted  in  diminished  IFN-y production  from cultures  stimulated  with  mitogen.  IL-4 and 
IFN-~/protein production by PBMCs and CD4 + T  cells stimulated with mitogen was assessed 
to see if we could detect a specific bias of cytokine production. Small amounts oflL-4 were de- 
tected  from CD4 +  T  cells  but  not  PBMCs  from most individuals  tested.  IFN-y and  IL-2, 
however,  were  also  produced  from these  same  cultures.  These  results  further  elucidate  the 
mechanism ofcytokine regulation in HIV- infected individuals, and they provide evidence that 
IL-15 may be a useful immune modulator. 
D 
uring the past 10 years, there has been an explosion in 
the number of new cytokines isolated and intense in- 
terest  in using them as  therapeutics.  IL-2, one of the  first 
cytokines to be isolated (1),  is a potent T  cell growth factor 
that  has been  used  successfully as  a  therapeutic  in  certain 
types of cancer (2).  More recently, it has been shown to be 
effective in  increasing  the  CD4 +  T  cell  count in patients 
infected  with  HIV  (3).  Another cytokine,  IL-12,  has  also 
been shown to exert a powerful regulatory influence of the 
cellular  immune  response  (4).  These  responses  are  most 
striking in several murine  models of intracellular infection 
(4).  There is also evidence to suggest that IL-12 may have a 
critical  function  in the  progression  of HIV disease  (5,  6). 
These studies have been a prelude to clinical trials  using IL- 
12 therapy in both cancer and AIDS. While these cytokines 
are  important  in  mediating  immune  responses,  it  is  clear 
that  redundancy  in  function  exists  among  various  cyto- 
kines, leaving the door open for new growth factors to be 
isolated and studied, which might ultimately provide thera- 
peutic benefit. 
Recently, a new cytokine was cloned on the basis  of its 
ability to cause proliferation of an IL-2-dependent cell line 
(7).  It was  given  the  designation  IL-15.  IL-15  appears  to 
have many functions similar to those of IL-2. For example, 
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and signal transduction (8).  Moreover,  IL-15  is  a  potent 
growth factor for activated T  cells and it enhances cytolytic 
function of both NK and CD8 + T  cells (7-9).  In striking 
contrast to IL-2, IL-15 is not produced from T  cells, but it 
is abundantly expressed by a wide variety of tissues and by 
activated  monocyte/macrophages  (7).  Herein,  using cells 
from both HIV  + and HIV- individuals, we study the effect 
that IL-15 has on both the proliferation and cytokine pro- 
duction. We also compare its effects to  those of IL-2 and 
IL-12 on modulating these reponses. Moreover, we exam- 
ine the role that endogenous IL-2, IL-12, and IL-15 have 
on IFN-2? production. 
In addition to studying the function that exogenous cy- 
tokines have on the immune response, there has also been 
interest in defining the endogenous response from HIV-in- 
fected patients by the particular types ofcytokines they pro- 
duce (i.e., Thl vs. Th2) (10-13). Most of the studies to char- 
acterize the immune response were done using PBMC as 
responder cells  (10,  12).  This population of cells contains 
multiple cell  types  that  can produce  the  same  cytokines, 
making it difficult to assess the production from CD4 +  T 
cells.  In the  present study,  using both  purified CD4  +  T 
cells and PBMCs from the same individual, we assessed  the 
IL-2, IL-4, and IFN-~/protein content in response to vari- 
ous antigens. By using purified CD4 + T  cells, we were able 
to specifically identify whether a Thl or Th2 type pattern 
was expressed from the same number of responding cells. 
The following studies highlight the prominent role that 
both endogenous and exogenous IL-2, IL-12, and IL-15 ex- 
ert on the immune response from patients infected with HIV. 
Materials  and Methods 
Reagents.  Complete media consisting of RPMI 1640 supple- 
mented with 10% heat-inactivated human AB serum from Sigma 
Chemical Co.  (St. Louis,  MO), penicillin (100 U/ml), strepto- 
mycin (100 U/ml), and L-glutamine (2 mM) were used  for all 
stimulations.  PHA was purchased from Grand Island Biological 
Co.  (Grand Island,  NY).  Tetanus toxoid  was  purchased  from 
Connaught Labs (Swiftwater,  PA).  Recombinant gp  120 was a 
generous gift from Genentech (San Francisco,  CA).  A group of 
five synthetic peptides  corresponding to the env of HIV-1  (T1, 
T2,  Th4.1,  P18IIIB,  and  pl8MN)  have  been  previously 
described  (14, 15). Mouse anti-human magnetic beads were pur- 
chased from Advanced Magnetic Inc. (Cambridge,  MA). Ficoll- 
Hypaque was purchased from Pharmacia  Fine Chemicals (Piscat- 
away, NJ). 
Subjects.  Whole blood was  obtained by venipuncture from 
healthy HIV volunteer donors and HIV-l-infected individuals. 
In some experiments, PBMCs  were  obtained from HIV-l-in- 
fected individuals by apharesis. All specimens were processed and 
plated into the appropriate  cultures immediately or within 16 h of 
the time the blood was collected. 
Recombinant  Lymphokines.  Human rlL-2 with a specific activ- 
ity of 6.5  X  106 BRMP  U/rag was purchased  from Genzyme 
Corp.  (Boston,  MA).  Human rlL-12 with a specific activity of 
5.26  ￿  106  U/rag was  purchased  from R.  &  D  Systems,  Inc. 
(Minneapolis, MN). Simian IL-15 with a specific activity of 5.8  ￿ 
105 U/l~g was provided by Immunex Corp. (Seattle, WA). 
Antibodies.  Humanized antibodies against the o~ chain (anti- 
TAC)  1  and ~ chain (anti-IL-2R.~) of the IL-2 receptor were a gen- 
erous gift of Dr. John Hakimi (Roche Laboratories,  Nutley, NJ). 
Goat anti-human  IL-12 antibody was purchased from P~ & D Sys- 
tems  Inc. Mouse anti-human antibodies  to  CD3,  CD8,  CD14, 
CD16,  CD19, and CD56 were gift from Dr.  Thomas Nutman 
(NIAID, NIH, Bethesda,  MD).  Antibody against human IL-15 
was provided by Immunex (Seattle, WA). 
Preparation of Cells.  PBMCs,  CD4  + T  cells, and APCs were 
prepared from the same starting population in the following man- 
ner: PBMCs were isolated from freshly drawn hepatinized  venous 
blood or buffy coat fractions by Ficoll-Hypaque density gradient 
centrifugation. T cell (E-rosette +) and APC (E-rosette-) popula- 
tions were isolated by rosetting PBMCs with neuraminidase-treated 
SRBC. For CD4 + T  cells purification, the E-rosette  + cells were 
resuspended at 2 ￿  107 cells per mt and mAbs (5 I-~g/ml)  to CD8, 
CD14, CD16, CD19, and CD56 were added for 30 rain at 4~ 
For APC purification, the E-rosette- cells were incubated under 
similar conditions with antibodies to CD3, CD8, CD16, and CD56. 
At the end of the incubation, both E-rosette + and E- rosette- 
cells were washed twice, and they were mixed with mouse anti- 
human magnetic beads for 30 rain at 4  ~  Positively  staining cells 
were depleted by two 20-min cycles of exposure  to a magnetic 
field. The remaining cells were washed twice in culture medium 
and used for studies. After this negative selection  procedure, the 
percentage of CD4  + T  cells ranged between 80 and 90%, while 
>90% of the cells in the APC population stained for CDI4 and 
CD19. In general,  <1% of the cells in either population stained 
positively for CD8 or CD16. At least one different HIV- control 
was used in each separate experiment. 
Measurement  of Proliferation in Response  to Stimulation.  PBMCs 
of HIV  + or HIV- individuals were suspended  at a concentration 
of 2.5  ￿  106 cells per ml in complete media. A total of 2.5 ￿  105 
cells were added to round-bottom 96 well plates (Nunc, Rosk- 
ilde, Denmark) and stimulated in vitro for 5-6 d with PHA (final 
concentration of 1/500), a group of five peptides from the Env of 
HIV-1  (final concentration of 2.5  p~M/ml), tetanus toxoid (final 
concentration of 1/3,000), or gp  120 (final concentration of 30 
p~g/ml). Various concentrations of simian IL-15 alone or in com- 
bination with TAC and IL-2[3 chain (MikB-l) at concentrations 
of 10 p~g/ml were added to the cultures.  In another group of ex- 
periments, PBMCs were stimulated with tetanus toxoid or HIV 
env peptides at the same concentrations as listed above in the pres- 
ence of media alone, rlL-2 (1 ng/ml), rlL-12 (20 U/ml), or sim- 
ian 1L-15 (5 ng/ml). After 5 d, cultures were pulsed with 1 p~Ci 
of [3H]thymidine and were harvested after 18 h. Results represent 
the mean of triplicate wells. The SEM was < 10% in all experiments. 
Induction  of Cytokine  Production  by  PBMCs  and  CD4  T  Cells. 
To induce cytokine production, PBMCs (2.5 ￿  10  s per well) or 
highly enriched CD4 § T cells (1  ￿  105 per well) plus APC (1  ￿ 
I04 cells per well)  were added  to round bottom 96-well plates 
and stimulated with PHA or tetanus toxoid in the  presence  of 
various  cytokines and/or anticytokines. Supernatants  were  col- 
lected  after 4-5 d of culture and stored  at  -70~  until used.  It 
was determined from several time course  experiments that opti- 
mal production of IL-2, IFN-~/and 1L-4 could be detected 4-5 d 
after stimulation with mitogen or specific antigen. 
Measurement  of Cytokine Production.  IL-2 content was assessed 
using an  1L-2-specific  ELISA kit  (Endogen, Cambridge, MA). 
IAbbreviations used in this paper, anti-TAC, humanized antibodies against 
the ~  chain of the IL-2 receptor; anti-lL-2R[3, humanized antibodies 
against the [3 chain of the IL-2 receptor. 
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HIV  + and HIV- Individuals in Response to Various Antigens 
Stimulus  HIV  +  HIV- 
Experiment I 
PHA(1/500) 
-  25,908  79,770 
Anti-IL-2R_B  35,673  61,550 
Anti-IL-15  11,222  36,778 
IL-15 (10 ng/ml)  240,457  259,321 
IL-15 +  anti-IL-2RB  45,497  54,438 
IL-15 +  anti-IL-15  16,146  63,309 
HIV pooled peptides 
-  2,151  762 
IL-15 (10 ng/ml)  79,809  2,099 
gp120 
-  14,864  333 
IL-15 (10 ng/ml)  44,614  100 
Experiment 2 
PHA (1/500) 
-  11,700  2,000 
Anti-IL-2RB  16,241  1,413 
Anti-TAC  5,213  1,361 
IL-15 (5 ng/ml)  45,000  3,900 
IL-15 (1 ng/ml)  17,300  2,700 
IL-15 (5 ng/ml) +  anti-IL-2R.B  20,000  3,500 
IL-15 (5 ng/ml) +  anti-TAC  22,809  4,000 
Tetanus 
-  9,467  12,220 
Anti-IL-2R.B  9,696  9,983 
Anti-IL-15  7,483  11,173 
Anti-TAC  1,448  951 
IL-15 (5 ng/ml)  30,400  23,100 
IL-15 (1 ng/ml)  17,300  14,900 
IL-15 (5 ng/ml) +  anti-IL-2RB  14,905  13,493 
IL-15 (5 ng/ml) +  anti-IL-15  11,336  8,824 
IL-15 (5 ng/ml) +  anti-TAC  9,849  4,616 
HIV pooled peptides 
-  200  100 
IL-15 (5 ng/ml)  8,900  800 
IL-15 (1 ng/ml)  1,300  200 
IL-15 (5 ng/ml) +  anti-II-2RB  800  300 
IL-15 (5 ng/ml) +  anti-TAC  3,300  100 
IL-15 did not show any activity in this assay. The lower limit of 
detection was 42 pg/ml. IL-4 was also assessed using an IL-4--spe- 
cific  ELISA  kit  (Endogen). The lower limit of sensitivity  was 
found to be 3-10 pg/ml, which was similar to the sensitivity ob- 
tained using hCT.4S in a bioassay. Moreover, we noted that IL- 
lS caused significant proliferation of the hCT.4S cells, obviating 
their use in situations where IL-15 is endogenously produced or 
added.  IFN-~/production was measured by ELISA as previously 
described (6). The lower limit of sensitivity was between 3 and 10 
U/ml. Results for all cytokines represent the mean of triplicate 
wells. The SEM was <10% in all experiments. 
Results 
IL-15  Increases  the  Proliferative  Response  to  Polyclonal 
Mitogen, Recall Antigen, and HIV-specific Antigen.  We  stud- 
ied whether IL-15 could enhance the proliferative response 
of PBMCs from both HIV- and HIV  +  individuals in re- 
sponse to various antigens. PBMCs were isolated and stim- 
ulated with a "suboptimal" concentration of PHA for 4  d. 
This allowed a window in which to study the function that 
various cytokines can have on the proliferative response to 
PHA, since at an optimal dose of PHA, the proliferative re- 
sponse is maximal and exogenous cytokines have little ef- 
fect. In Experiment 1 (Table 1), the HIV  + individual had a 
ninefold increase in PHA-induced proliferation in the pres- 
ence oflL-15, compared to a fourfold increase in the HIV- 
control, bringing the response of the HIV  + donor to a level 
comparable to that of the HIV- control. Cells stimulated in 
the presence of both IL-15 and an antibody to IL-21k[3  or 
IL-15 showed similar values to the response obtained in the 
absence of exogenous IL-15, proving that the effect oflL-15 
was specific. Moreover, anti-IL-2R.[3 or anti-IL-15 did not 
appreciably diminish the baseline response. In the same ex- 
periment, the  moderate baseline proliferative response  to 
two  different  HIV-specific  antigens  (gp120  and  pooled 
peptides)  is  also  shown  to  be  strikingly increased in  the 
HIV-infected individual when  IL-15  is  present,  whereas 
the  HIV-  individual had  essentially no  response  in  the 
presence  or  absence  of  IL-15.  Experiment  2  (Table  1) 
shows additional data using tetanus toxoid as a recall anti- 
gen to stimulate the cells. Both the HIV  + and HIV- indi- 
viduals generated a baseline response to tetanus alone. Pro- 
liferation  was  increased  approximately  threefold  in  the 
HIV  + individual and twofold in the HIV- individual in the 
presence of IL-15. We also tested whether anti-TAC influ- 
enced the IL-15-induced response. Anti-TAC caused sub- 
stantial inhibition of the baseline proliferative response to 
tetanus, whereas anti-IL-2R[3 had no effect.  These results 
are  compatible  with  previous  work  demonstrating anti- 
The effect oflL-15 on proliferation of PBMCs from HIV + and HIV- 
individuals in response to various antigens. Fresh PBMCs were added 
(2.5 ￿  10s/200 I~1) to 96-well plates (round bottom) in the presence of 
the following antigens; PHA  (1/500 final dilution), pooled HIV  env 
peptides (2.5 I~M final concentration), gp 120 (30 ~g/ml),  or tetanus 
(1/3,000 dilution). IL-15 was added at the concentrations indicated. 
Antibodies to IL-15, etTAC, and IL-2RB were added at a concentra- 
tion of 10 p~g/ml. In the absence of antigen, cpm were <1,000  from 
PBMCs of both HIV + and HIV- individuals in both experiments. In 
Experiment 1, cpm for cells cultured in the presence oflL-15 alone (10 
ng/ml) were 1,500 and 6,000 for HIV + and HIV- individuals,  respec- 
tively, in Experiment 2, cpm were 8,300 and 5,500, respectively, for 
HIV  + and HIV- individuals.  Background values for IL-15 alone were 
subtracted from values obtained in the presence of antigen plus IL-15. 
The data are combined from two separate experiments. 
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ative response  than anti-IL-2R~  (8,  16).  When  IL-15  was 
added  in  the  presence  of anti-TAC,  there  was  a  threefold 
decrease  in  the  response  compared  to  IL-15  alone,  but  a 
sevenfold increase  compared  to when anti-TAC alone was 
added.  This  suggests  the  baseline  proliferative  response  to 
tetanus is mediated in large part by IL-2, and the increase in 
proliferation seen with IL-15 is augmented  by endogenous 
IL-2 production.  PBMCs from both HIV + and HIV-  indi- 
viduals  showed  essentially  no  baseline  proliferation  (cmp 
<1000)  in  response  to  HIV  pooled  peptides.  Cells  from 
HIV +  individuals,  however,  when  stimulated  in  the  pres- 
ence  of 1L-15,  had  a  striking increase  in  proliferation  that 
was completely abrogated when anti-IL-2R~  was added in 
the  cultures.  Interestingly,  anti-TAC  inhibited  the  IL-15- 
mediated  increase  threefold.  These data also supported  the 
notion  that  IL-15  is  enhancing  a  response  in  which  small 
amounts  of endogenous  IL-2  are  produced.  It  should  be 
noted  that  although  no  proliferation  was  seen  in  the  ab- 
sence of exogenous IL-15,  it is clear from earlier work us- 
ing the same HIV peptides  that  IL-2 can be detected from 
cultures that do not show a proliferative response.  Thus,  al- 
though  no proliferation is seen,  small amounts  of IL-2 tnay 
be present in these cultures (14,  15). 
IL-2,  IL- 12,  and IL- 15 Increase the Proliferative Response 
to Recall Antigens and HIV-specific Antigen.  It  was  recently 
demonstrated  that  IL-I2  strikingly  enhanced  proliferation 
of PBMCs  from HIV §  individuals  in  response  to  recall or 
HIV-specific antigens  (6).  We  compared  the  effect of ex- 
ogenous IL-2, IL-12, and IL-15 on proliferation of PBMCs 
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Figure  1.  Proliferation  of  PB- 
MCs from HIV  + and HIV  individ- 
uals stimulated  with  tetanus  toxoid 
and  HIV  pooled  peptides  in  the 
presence  of IL-2,  IL-12,  and 1L-15. 
Fresh  PBMCs  were  added  (2.5  ￿ 
10s/200  btl) to 96-well  plates (round 
bottom) and stimulated by a group  ot 
pooled HIV Env peptides  (2.5 btM 
final concentration)  or tetanus  tox 
old  (1/3,000  dilution)  in  the  pres- 
ence or absence of IL-2  (1  ng/ml), 
IL-12 (20 u/ml), or IL-15 (5 ng/ml) 
for 5 d and then pulsed with  1 I~Ci 
of[3H] thymidine, and harvested 18 h 
later. Results are reported as cpm. As 
a control, PBMCs were cultured  for 
the same period  in  the presence  of 
the  various  cytokines  but  without 
any antigen  stimulation.  In each in- 
dividual,  the  background  value  for 
cells cultured  in cytokine  alone was 
subtracted  from  the  value  obtained 
when cells were cultured  with anti- 
gen and cytokine. The data are pooled 
from more  than  eight  experiments. 
At least one  HIV-  control  was  in- 
cluded  in each separate experiment. 
The P values shown were calculated 
by  a Wilcoxon signed  rank  test  by 
comparing the  cpm  when  cells are 
stimulated with antigen alone vs. an 
tigen in the presence of [L-2, IL-12, 
or IL-15. 
1070  Cytokine Interactions in HIV-infected Individuals Table 2.  tL-12 Increases tL-2 Production  from PBMCs 
Stimulated with PHA 
PBMC 
CD4 count  Stimulus  -  IL-15  o~TAC oLTAC +  IL-15 
Experiment 1 
1,100  PHA  0  0  596  612 
TET  0  0  0  0 
420  PHA  0  0  2,100  2,100 
TET  0  0  0  0 
80  PHA  0  0  750  750 
TET  0  0  0  0 
HIV-  PHA  0  0  1,500  1,200 
TET  0  0  120  122 
PBMC 
Experiment 2  -  IL-12  o~TAC otTAC +  IL-12 
240  PHA  0  800  780  4,200 
TET  0  18  0  100 
600  PHA  0  1,600  2,700  5,700 
TET  0  0  0  0 
<200  PHA  0  109  681  1,051 
TET  0  0  0  0 
1,100  PHA  0  0  234  910 
TET  0  0  0  0 
HIV-  PHA  0  105  1,200  7,000 
TET  0  0  73  59 
HIV-  PHA  0  0  573  783 
TET  0  0  444  263 
CD4 + T cells 
240  PHA  1,900  3,000  1,800  4,500 
TET  0  0  0  0 
600  PHA  2,700  2,100  2,100  4,000 
TET  0  0  0  0 
<200  PHA  1,536  1,719  1,634  1,923 
TET  0  0  0  0 
1,100  PHA  1,507  2,096  1,677  2,281 
TET  0  0  0  0 
HIV-  PHA  190  340  900  1,500 
TET  85  0  235  171 
HIV-  PHA  500  800  1,000  2,100 
TET  64  0  80  75 
Effects of IL-12 and IL-15 on IL-2 production from PBMCs and 
CD4 + T ceils in response to PHA and tetanus (TET). PBMCs (2.5 ￿ 
105/200 p~l) or highly enriched CD4 + T cells (105/200 I~1) plus APC 
(10  4 cells) were added to 96-well plates in the presence of PHA (1/100 
final concentration) or tetanus (1/3,000 final concentration). In Experi- 
ment l, IL-15 (5 ng/ml), anti-TAC (10 Ixg/ml), or both were added to 
cultures. In Experiment 2, IL-12 (20 U/ml), anti-TAC, or both were 
added to cultures containing PBMCs or CD4 + T  cells. Supematants 
were collected after 4-5 d and IL-2 content was measured by ELISA 
(Endogen, Cambridge, MA). The sensitivity  of the IL-2 ELISA was 42 
pg/ml. Values shown are in picograms per milliliter. Total CD4 counts 
from  HIV  +  and HIV-  individuals in response  to  tetanus 
toxoid or a group of HIV peptides. HIV  § individuals were 
segregated  into  three  groups  based  on  their  total  CD4 
count  (<200,  200-500,  >500/Ixl)  and  compared  to  a 
group of HIV- individuals with CD4  counts of generally 
>1,000/1~1. HIV- individuals demonstrated a good prolif- 
erative response to tetanus toxoid that was not enhanced by 
IL-2, IL-12, or IL-15 (Fig.  1 A). By contrast, HIV  + indi- 
viduals with CD4 counts <200/~1 showed no proliferation 
to  tetanus toxoid in the  absence of exogenous cytokines, 
but some  enhancement of the  response was  noted in the 
presence of all three cytokines. Patients with CD4  counts 
between  200  and  500  and  >500/Ixl  showed  increased 
baseline proliferation from  the  <200/Ixl  group,  and  this 
was  enhanced approximately twofold by IL-2  and IL-15, 
but not by IL-12. Thus, it appears that IL-12 had its most 
dramatic  effect  in  two  of the  patients with  CD4  counts 
<200 per p2, while IL-2 and IL-15 had effects in all groups 
tested. To characterize the HIV-specific responses, a group 
of five synthetic peptides corresponding to  regions of the 
HIV-1  envelope used previously to characterize HIV-spe- 
cific proliferative and cytokine responses were tried (6,  14, 
15).  Proliferation of PBMCs in response to these peptides 
from  HIV-  individuals in  most  instances was  very  low 
(cpm< 1,000), although when stimulated in the presence of 
IL-2, there was significant proliferation (Fig. 1 B). Addition 
of IL-15  caused  only a  modest  increase  in  proliferation 
(1,000 cpm above background), while IL-12 did not cause 
any increase in proliferation. These results make it difficult 
to assess the ability oflL-2 to "restore" a deficient response 
in the  HIV  +  individuals. In this regard,  IL-12 and IL-15 
would provide more specific data.  HIV  §  individuals in all 
groups  had  litde proliferative response  to  the  peptides in 
the absence of exogenous cytokines (Fig.  1 B).  In patients 
with CD4 counts of 200-500 or >500/txl, IL-12 and IL- 
15 caused a modest increase in proliferation. The failure to 
detect a substantial baseline proliferative response from the 
HIV  +  individuals  contrasts  with  the  data  obtained  by 
Clerici et al.  (6).  This might be  explained by the  patient 
population and at which stage of disease they were tested. 
The ability oflL-12 to enhance the proliferative response is 
consistent with their data (6), although their responses were 
substantially greater.  A  major caveat to these studies, as in 
most studies on cells from HIV  + patients, is that the patient 
groups are relatively small and variable in disease states, and 
the SE ranges are substantial. 
IL-12  Significantly  Increases IL-2  Production from  PHA- 
stimulated PBMCs.  Since IL-15  affected  T  cell prolifera- 
tion, which  is  usually IL-2--dependent, it was  of interest 
whether IL-15 might affect IL-2 production. PBMCs from 
patients with varying CD4 + T  cell counts were stimulated 
by PHA or tetanus in the presence of IL-15, anti-TAC, or 
IL-15  +anti-TAC.  The  use  of anti-TAC prevents  IL-2 
of the HIV- infected patients are listed in the left-hand column. Most 
HIV- controls had CD4 counts > 1,000. The data are combined from 
two separate experiments. 
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has accumulated.  Table 2  (Experiment  1)  shows that IL-15 
does not enhance the IL-2 detected in response to PHA  or 
tetanus  compared  to  anti-TAC  alone.  We  also  examined 
the effect of IL-12 on IL-2 production.  Previous work has 
shown  that  IL-12 increased proliferation and  IL-2 produc- 
tion from PBMCs  in response  to HIV-specific antigen  (6). 
Table  2  (Experiment  2)  shows  combined  results  from two 
separate experiments.  In these experiments,  the presence of 
IL-12 alone was  able to enhance  IL-2 production,  even in 
the absence  of anti-TAC,  demonstrating  the striking effect 
it has on IL-2 production.  When both anti-TAC and IL-12 
were added  to  cultures,  IL-2 production  was  strikingly in- 
creased from PBMCs  of both  HIV + and HIV-  individuals. 
By contrast,  IL-t2  had  only a  modest  effect on  increasing 
IL-2 from highly enriched CD4 + T  cells, particularly in in- 
dividuals  with  low  CD4 +  T  cell  counts.  Moreover,  IL-2 
production  induced  by  a  CD4/class  II-restricted  antigen 
such  as tetanus  was  not  enhanced  using PBMCs  or CD4 + 
T  cells. These results and other data not shown suggest that 
IL-12  may  be  enhancing  IL-2  production  from  CD8 +  T 
cells,  or  that  enhancement  depends  on  the  presence  of 
other cells removed when the CD4 + T  cells are purified. 
Early experiments studying proliferation or IL-2 produc- 
tion  from  cells  of HIV-infected  patients  stimulated  with 
PHA or tetanus raised the issue of whether a qualitative de- 
fect  of 1L-2  production  existed  in  these  patients  (17-24). 
The  data  in  Table  2  (Experiment  2),  show that  IL-2 pro- 
Table 3.  Addition of lL- 12 Enhances IFN-T Production  fiom PBMCs or CD4 + T Ceils Stimulated with Antigen 
PBMC 
CD4 count  -  IL-2  IL-12  IL-15 
Experiment 1 
1,100  PHA  540  525  600  500 
TET  0  0  40  0 
420  PHA  285  500  800  270 
TET  7  100  210  40 
80  PHA  40  50  560  35 
TET  0  0  0  0 
HIV-  PHA  220  270  1,800  90 
TET  12  27  375  24 
PBMC 
Experiment 2  -  IL-2  IL-12  IL-15  etTAC  e~12  otTAC +  12  cxlL-15 
240  PHA  305  520  1,050  425  0  110  570  100 
TET  0  70  180  12  0  0  140  ND 
600  PHA  600  500  515  600  250  175  410  400 
TET  0  30  120  7  0  0  70  ND 
HIV  PHA  275  375  635  500  10  60  470  200 
TET  22  70  280  45  0  10  220  ND 
CD4 + T  cells 
--  IL-2  IL-12  IL-15  sTAG  or12  aTAC +  12 
240  PHA  165  165  350  20  20  85  320 
TET  0  0  36  0  0  0  14 
600  PHA  185  235  810  200  0  65  420 
TET  0  0  0  0  0  0  0 
HIV-  PHA  25  50  220  40  0  0  185 
TET  0  5  60  0  0  0  50 
Effects oflL-2, IL-12, and IL-15 on IFN-~ production from PBMCs and CD4 + T cells in response to PHA and tetanus.  PBMCs (2.5 ￿  105/200 
I*1) or highly enriched CD4 + T cells (105/200  ~1) plus APC (104 cells) were added to 96-well plates and stimulated  with PHA or tetanus in the pres- 
ence oflL-2 (1 ng/ml), IL-12 (20 U/ml), or 1I.-15 (5 ng/rrd).  In Experiment 2, anti-TAC, anti-IL-12 (10 ~g/ml), anti-TAC +  1L-12, or anti-/L- 
15 (10 b~g/ml) were added  to the cultures.  Supernatants  were collected atier 4 d and IFN-3' content was measured  by ELISA. The sensitivity of the 
assay was between 3 and 10 U/nil. Values shown are in units per miUiliter. The data represent two separate experiments. 
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in  response  to  PHA  in  HIV  +  individuals  compared  to 
HIV- controls. This could be explained if a greater number 
of the  responding  cells  from  the  HIV  +  individuals were 
previously activated. Although PHA may not be a "physio- 
logic"  stimulus,  these  results  suggest  that  under  maximal 
stimulation conditions, there  is not  a  deficit of IL-2 pro- 
duction when  controlling for an  equal  number  of CD4 + 
responder cells from both HIV + and HIV- individuals. 
IL-12  Strikingly Enhances  IFN-T Production  in Response to 
Antigen Compared to IL-2 or IL-15.  IL-15  was  compared 
to IL-2 and IL-12 in its ability to alter IFN-~/ production 
by PMBC  or CD4 + T  cells in response to PHA or tetanus 
toxoid. The presence of exogenous IL-2 and IL-15 had lit- 
tle effect on IFN-y production  (Tables 3  and 4).  By con- 
trast,  cells  stimulated  in  the  presence  of  IL-12  show  a 
marked increase in IFN-~/production from both the HIV + 
and  HIV-  individuals in response  to  both  stimuli.  IFN-~/ 
measured from PBMCs  stimulated with HIV peptides was 
often below the limit of detection and was  not  enhanced 
by  the  presence  of IL-15,  although  in  selected  patients, 
there was a response when IL-12 was added to the cultures 
(data not  shown).  These  results suggest that  IL-15  (5  ng/ 
ml), at a dose sufficient to elicit maximal proliferation of T 
cell blasts (7), does not augment IFN-~/production. Inter- 
estingly, when the dose of lL-15 was increased to 100 ng/ 
ml, there was an increase in spontaneous IFN-~/production 
from  PBMCs.  Whether  this  "high"  dose  of IL-15  elicits 
IFN-'y from NK cells in a similar manner to IL-2 is being 
examined. Moreover, at this dose of IL-15, IFN-~/was also 
increased in  response  to  tetanus  toxoid and  HIV-specific 
antigen (data not shown). 
Neutralization of Endogenous IL-2, IL-12,  or IL-15 Reduces 
IFN- y  Production in Response to PHA.  We  analyzed  the 
effect of inhibiting endogenous IL-12, IL-15, or binding of 
IL-2 to various subunits of its receptor on the in vitro pro- 
duction of IFN-%  Neutralization of either IL-2ILet (anti- 
TAC)  or IL-12 resulted in substantial inhibition of IFN-~/ 
(Table 4). When the IL-21Lc~ was blocked in the presence 
of IL-12, however,  there was partial restoration of the re- 
sponse.  These  results demonstrate the importance  of both 
of these cytokines for optimal IFN-y production. Neutral- 
ization oflL-15 also resulted in a two- to threefold decrease 
in IFN-~/production. This effect seemed more pronounced 
in the HIV-infected patients than in the HIV-  individuals 
(Table  4).  Moreover,  the  presence  of anti-IL-2K[3  chain 
antibody to  PHA-stimulated cultures resulted in  a  similar 
degree of inhibition as did the anti-IL-15 (Table 4, Experi- 
ment 1), consistent with data showing that IL-15 acts through 
this subunit of the IL-2 receptor (7-9). 
IL-2,  IL-12,  and IL-15 Do Not Alter IL-4 Production from 
PBMCs or PHA-stimulated CD4  + T  Cells.  There has been 
Table 4.  Antibodies against IL-12, IL-15, and Receptors  for IL-2 Decrease IFN-7 Production  from PBMCs and CT4  + T Cells Stimulated 
with PHA 
PBMC 
CD4 count  -  IL-2  IL-12  IL-15  aTAC  ~x12  ~xTAC+ 12  etl5  otlL-21~[3 
Experiment 1  491  750  570  900  650  55  ND  ND  275  265 
613  1,000  920  950  900  500  ND  ND  530  600 
HIV-  600  500  500  500  200  ND  ND  320  310 
PBMC 
CD4 count  -  IL-2  IL-12  IL-15  aTAC  ot12  e~TAC+ 12  ot15  otlL-2R.[3 
Experiment 2  155  1,900  1,400  2,000  1,000  225  600  1,050  600  ND 
1,129  180  200  850  300  0  75  370  80  ND 
HIV-  400  400  950  500  0  150  700  500  ND 
CD4 + T cells 
155  140  150  1,650  100  0  55  950  0  ND 
1,129  150  200  1,100  275  60  110  630  100  ND 
HIV-  550  750  2,500  575  250  250  2,500  200  ND 
Effects of anticytokines and anti~zytokine receptor antibodies on IFN-"/production from PBMCs and CD4 + T cells  in response to PHA. PBMCs 
(2.5 ￿  105/200 b~l) or highly enriched CD4 + T cells (105/200 ~1) plus APC (10  4 cells) were added to 96-weU plates and stimulated with PHA of 
IL-2 (lng/ml), IL-12 (20U/ml), or IL-15 (5 ng/ml. Anti-TAC (10~zg/ml), anti-IL-12 (10 ~g/ml), and anti-15 (10~g/ml), or anti-IL-2R[3  (10~g/ 
ml) antibody were added to the cultures as indicated in the table. Supematants were  collected after 4 d and IFN-~/ content was measured with 
ELISA. The sensitivity of the assay  was between 3 and 10 U/nil. Values shown are in units per milliliter. The data are combined from two separate 
experiments. 
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duction  from  cells  of HIV  +  individuals  to  determine  if 
there  is  a  bias  toward  a  Thl-  or  Th2-type  cytokine  re- 
sponse  (10-13).  Previous  studies  measuring  IL-4  protein 
used  PBMCs  as  responder cells in  the  culture  to  various 
mitogens (10).  Since multiple cell types can produce IL-4, 
and the Thl/Th2  paradigm is based on CD4-produced cy- 
tokines,  we  assessed  IL-4  protein  content  from  both 
PBMC  and  CD4 +  T  cells in response to PHA by using a 
sensitive  IL-4-specific ELISA.  PBMCs  produced  little or 
no IL-4 from both HIV + and HIV- individuals. When IL-4 
was  measured  from highly enriched  CD4 +  T  cells, how- 
ever, small amounts  were detected from both groups  (Ta- 
ble 5).  IL-2 and IFN-~ were also measured from the same 
supernatants to determine if there was a predilection toward 
Thl  or Th2  cytokine production.  In all cases,  both  IL-2 
and  IFN-'y were  detected in both  HIV +  and  HIV-  indi- 
viduals. Moreover, production oflL-4 and IFN-',/were not 
substantially different among the two populations studied. 
Interestingly,  the  highest  amount  of  IL-4  was  detected 
from an HIV + patient with a CD4 count of 1,100. 
Lastly,  the  effects  of exogenous  IL-2,  IL-12,  or  IL-15 
Table 5.  IL-4 Production  from PBMCs and CD4  + T Cells 
Stimulated with PHA Is Not Affected by the Addition of lL-2, 
IL- 12, or IL- 15 to Cultures 
PBMC 
CD4count  Stimulus  -  IL-2  IL-12  IL-15 
IL-2  IFN-',/ 
<200  PHA  0  0  0  0  681  1,900 
240  "  0  0  0  0  780  305 
600  "  0  0  0  0  2,700  600 
1,100  "  15  17  13  17  234  180 
HIV-  "  13  9  15  8  1,200  275 
HIV-  "  0  0  0  0  573  40 
CD4 + T cells 
IL-2  IFN-~ 
-  IL-2  IL-12  IL-15 
<200  PHA  61  51  39  76  1,634  140 
240  "  7  10  11  13  1,800  165 
600  "  5  5  6  8  2,100  185 
1,100  "  155  137  21  147  1,677  150 
HIV-  "  36  30  24  30  1,000  25 
HIV-  "  65  45  40  53  900  550 
Effects oflL-2, IL-12, and IL-15 on IL-4 production from PBMCs and 
CD4 + T  cells in response to PHA.  Cells were  cultured under similar 
conditions outlined in Tables 2 and 3. Culture  supernatants were col- 
lected after 4-5 d and IL-4 content was measured by ELISA (Endogen). 
The sensitivity of the IL-4 ELISA was 3 pg/ml. Values shown for the 
IL-4 are in pg/ml. IL-2 and IFN-~/content were measured as described 
in Tables 2 and 3. The data are combined from two separate experi- 
ments. 
were  examined  for  their  ability to  alter  IL-4  production 
from PHA-stimulated cells. These cytokines appear to ex- 
ert no demonstrable influence on IL-4 production in these 
short-term in vitro cultures. 
Discussion 
These studies were designed to characterize the effects of 
a newly recognized cytokine, IL-15, and compare it to IL-2 
and  1L-12  in  its ability to  alter cytokine production  and 
proliferation of both PBMC  and CD4 + T  cells in response 
to  a  panel  of antigens.  We  were  especially interested  in 
whether  IL-15  could  effect  an  HIV-specific  response  as 
well as to recall antigen. The quantitation and specificity of 
the HIV-specific response was complex. Initially, envelope 
proteins, gp160 derived from baculovirus and gp41 derived 
from Escherichia coli, were used as antigens. In several exper- 
iments,  they  consistently  induced  proliferative  responses 
from HIV- individuals and often elicited no responses from 
HIV + individuals, suggesting a high false positive response, 
and making their usefulness as an HIV-specific antigen lim- 
ited for these types of studies. We then used a group ofenv- 
derived  peptides  that  have  been  well  characterized  and 
studied for these purposes (6,  14,  15). These peptides elic- 
ited  essentially  no  proliferation  from  HIV-  individuals, 
making them useful for studying HIV-specific responses. It 
should  be  noted  that  the  proliferative responses  detected 
from HIV + patients at several stages of disease was also very 
low, similar to the HIV-  group. Although the proliferative 
response  to  the HIV peptides was  low,  addition of IL-15 
strikingly enhanced the response to the peptides as well as 
to tetanus toxoid from the HIV-infected individual (Table 
l). The effects of IL-15 were abrogated by addition of ei- 
ther antibody to IL-21L[3 or IL-15 to the cultures, demon- 
strating IL-15 specificity. Moreover, the enhanced prolifer- 
ation seen with  IL-15 appeared to be synergistic with the 
endogenous IL-2 produced. 
The  second question we studied was  the effect that  IL- 
l5  had  on  cytokine  induction  after  short-term  in  vitro 
stimulation. At doses that have been shown to induce max- 
imal proliferation on activated T  cells (1-5 ng/ml)  (7),  IL- 
l5  had  no  appreciable effect on  altering the  in  vitro pro- 
duction of IL-2, IL-4, or IFN-~ in response to any of the 
antigens tested from either HIV + or HIV- individuals (Ta- 
bles 2-5).  It is possible that higher doses of IL-15 may ef- 
fect cytokine induction. Several experiments using 10  ng/ 
ml of IL-15 gave similar results. However,  when  100  ng/ 
nil of IL-15 was used, there was an increase in IFN-~/pro- 
duction  from  cells  cultured  in  the  absence  of  antigen. 
Moreover,  PBMCs  stimulated  with  tetanus  toxoid  or 
HIV- peptides in the presence of 100 ng/ml of IL-15 had a 
significant increase in  IFN-~ production  above  that  seen 
when cells were cultured with IL-15 in the absence of anti- 
gen.  Interestingly,  IL-15  at  100  ng/ml  did  not  increase 
IFN-~  production  by  PHA-stimulated PBMCs  (data  not 
shown). It is possible that IL-15 at a "high" dose may cause 
IFN-~ production from previously activated T  cells or NK 
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in which IL-2 production is submaximal,  as would be the 
situation  when PBMCs from HIV-infected individuals  are 
stimulated with tetanus  or HIV- peptides.  Additional evi- 
dence that high dose IL-15 can increase IFN-~/production 
is supported by data obtained in a murine model of T  cell 
priming. The presence oflL-15 at 300 ng/ml caused an in- 
crease  an  IFN-~/  production  from  highly  purified  naive 
murine  CD4 + T  cells from TCR. transgenic mice that had 
been primed in vitro and restimulated,  supporting its role as a 
Thl-inducing cytokine (Seder,  R., manuscript submitted for 
publication). To study the role that endogenous IL-15 plays 
in  IFN-~/  induction,  we  added  a  neutralizing  antibody 
against IL-15 to PHA-stimulated PBMCs.  There appeared 
to  be  a  two-  to  threefold  decrease  in  IFN-~  in  cultures 
from HIV-infected patients,  but less  inhibition  in  cultures 
from the  HIV-  controls  (Table  4).  This  interesting  result 
may reflect the capacity of various infectious agents to in- 
duce  IL-15  in  HIV-infected  individuals.  Recent  work  in 
the murine system has shown that LPS, mycobacteria, and 
various parasites were capable of eliciting mRNA for IL-15 
from  macrophages  (Doherty,  M.,  personal  communica- 
tion). 
Previous studies have shown IL-12 to be a potent regu- 
lator of T  cell differentiation toward an IFN-'y-dominated 
response (26-28). Clerici et al. demonstrated that IL-12 could 
"restore"  a  deficient  proliferative  response  using  PBMCs 
from  HIV-infected  individuals  stimulated  with  an  HIV- 
specific antigen  (6).  They also noted that exogenous IL-12 
caused  a  significant  increase  in  IFN-~/  production  from 
these  patients,  but not the  HIV-  controls.  In our studies, 
IL-12 also had several striking effects. First,  IL-12 caused a 
2-10-fold increase in IFN-~/from both PBMCs and highly 
enriched  CD4 + T  cells of HIV  + and HIV- individuals  in 
response  to  PHA  or tetanus  toxoid  (Table  3).  Moreover, 
IL-12 was  able  to  elicit  IFN-~  production  in  several  in- 
stances in which there was no IFN-~ produced with anti- 
gen alone.  The role that endogenous IL-12 and IL-2 play 
in IFN-~ production was assessed by using neutralizing an- 
tibody to IL-12 or anti-TAC, respectively (Tables 3 and 4). 
Cultures  in  which  anti-TAC  was  added  had  essentially 
complete inhibition  of IFN-~ production, while  the pres- 
ence ofanti-IL-12 resulted in a two- to fivefold decrease in 
IFN-~ production. Interestingly, when IL-12 was added in 
the presence of anti-TAC,  it could partially restore the re- 
sponse.  These  data underscore the critical need for at least 
some IL-2 to optimally generate IFN-~/production. As we 
noted above, neutralization of IL-15 also caused a decrease 
in  IFN-'y production,  especially  in  HIV-infected  patients 
(Table  4).  Since there  is marked  redundancy in  the  func- 
tions of cytokines,  it  is interesting  to speculate  that  IL-15 
could act as a compensatory mechanism to IL-2 in situations 
in which IL-2 is diminished,  as could occur in HIV infec- 
tion.  We are currently studying whether IL-15 can restore 
IFN-~/production in cultures where IL-2 is neutralized. 
IL-12 also showed significant effects on increasing  IL-2 
production from PHA-stimulated PBMCs.  This effect was 
not as dramatic when highly enriched CD4 + T  cells were 
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used  as  responders.  Moreover,  responses  to  tetanus  were 
not significantly effected by IL-12. This brings up the ques- 
tion of whether IL-12 is having a more beneficial response 
on CD8 + T  cells to produce IL-2. Preliminary data using 
highly enriched CD8 + T  cells suggests that IL-12 is able to 
enhance  IL-2  production  from  this  cell  population.  Our 
data are similar  to those obtained by Clerici et al.  in their 
demonstration  that  IL-12 increased proliferation  and  IL-2 
production in HIV-infected patients  in response  to PHA. 
Additionally, they showed exogenous IL-12 increased IL-2 
production by PBMCs stimulated with  HIV-specific pep- 
tides or recall antigen (6).  It is possible that the low or ab- 
sent response to tetanus toxoid in our experiments may re- 
flect the  delayed kinetics  compared to the  PHA response, 
since Clerici et al. measured IL-2 after 7 d rather than 4--5 d 
in which we harvest our supernatant from. In experiments 
to  address  this  issue,  we  compared  IL-2 production  from 
supernatants  after 5  and 7  d  of culture in response to teta- 
nus toxoid or HIV- peptides.  IL-2 production was not en- 
hanced when IL-12 was added to PBMCs stimulated for 5 
or 7 d with tetanus toxoid or HIV pooled peptides, whereas 
IL-12  did  cause  a  two-  to  fivefold  increase  from  PHA- 
stimulated cells (data not shown). 
A  final issue addressed in this paper was whether PBMC 
or purified CD4 § T  cells taken from HIV-infected individ- 
uals  at  various  stages  of their  disease  exhibited  a  specific 
Thl  or Th2  pattern  of cytokine production.  Our  results 
from a relatively small number of patients  do not demon- 
strate a distinctive pattern ofcytokine production related to 
the  stage  of HIV disease.  Moreover,  we  found that  both 
HIV  +  and  HIV-  individuals  produced  both  IFN-~/  and 
IL-4 (Table 5), and that the HIV  §  individuals produced as 
much if not more of these  cytokines in response to PHA. 
These results appear to be consistent with recent data pub- 
lished by Graziosi et al.  showing that anti-CD3  stimulated 
cells from patients  at various stages of disease  had mRNA 
for all  of these cytokines (13).  By contrast,  a recent report 
by Maggie et al. showed a reduction of both IL-4 and IFN-~ 
from HIV  § PBMCs in response to anti-CD3 plus PMA (12). 
It is possible that the patient populations or the type of stim- 
ulus could explain these results.  Differences that might ex- 
plain why our data are different from experiments showing 
a deviation to a specific T  helper response may again  result 
from  differing  patient  populations  or  the  specific  way  in 
which subgroups of patients who produce IL-4 are defined. 
In conclusion, although our data do not show a distinctive 
pattern ofcytokine production, it does not preclude a role of 
distinct  types of cytokine production occurring in  a  certain 
group  of patients.  To  definitively  address  the  issue,  large 
numbers  of patients  could  be  monitored  throughout  the 
course of their disease to determine  if and when these spe- 
cific T  phenotypes occur. 
The goal of these studies is to examine the mechanism of 
cytokine interaction  to devise  treatment  strategies  for dis- 
ease.  Immune mechanisms that could be useful in treating 
HIV disease  would  be  to  augment  cytolytic activity,  en- 
hance cellular immunity, or generate neutralizing antibody. 
As noted earlier,  IL-2 has been shown to be a useful thera- peutic agent in many instances although it has been associ- 
ated with significant toxicity. Since IL-15 is similar to IL-2, 
in its ability to enhance cytolytic function of CD8 §  T  and 
NK cells, it might provide therapeutic benefit in those situ- 
ations in which IL-2 is effective. Moreover, if IL-15 is able 
to mimic the effects of IL-2 with less toxicity, it might be a 
useful treatment in diseases such as cancer or AIDS. Toxic- 
ity studies in mice have shown IL-15 to have a sixfold re- 
duction in  capillary leak and pulmonary edema  compared 
to IL-2 (28a).  IL-15 could be combined with  other cyto- 
kines (i.e.,  IL-12) to augment immune function and mini- 
mize  toxicity.  We  have  preliminary  data  in  both  human 
and  murine  systems  which  suggest  that  IL-12  and  IL-15 
can have additive effects on proliferation.  This is consistent 
with  recent  data by Carson et al.  showing that  IL-12 and 
IL-15 have a synergistic effect in augmenting NK cytolytic 
activity  and  IFN-~/  production  (9).  In these  studies,  as in 
others, IL-12 appears to be a good candidate for a therapeu- 
tic application based on its ability to augment cytolytic ac- 
tivity and enhance a cell-mediated response.  For example, 
if a cellular immune response characterized by production 
oflFN-~/and IL-2 is desirable, the rationale for using IL-12 
as it relates to its effects on increasing IFN-~/from CD4 + T 
cells could be twofold. The first would be to change a Th2 
to Thl  response.  The second reason would be to restore a 
"deficient"  cytokine response or enhance  a relatively nor- 
real  response  above  a  critical  threshold  that  would  be 
needed to protect the host. In examining the first rationale, 
even if distinctive Thl  or Th2 patterns  exist,  there is little 
evidence that those CD4 + T  cells that are already immuno- 
logically  committed  can  be  functionally  altered  by  cyto- 
kines  (28). Moreover, in situations in which CD4 + T  cells 
have  differentiated  into  a Th2 phenotype,  IL-12, through 
its  ability  to act as  a  T  cell growth  factor,  could  enhance 
this  response  (29,  30).  It is  more likely  that  IL-12 would 
exert an influence toward a Thl  response on a naive T  cell 
that had not yet encountered antigen or a cell that has been 
activated  by antigen  but  is not fully committed,  such  as  a 
Th0 cell.  Thus, if cytokine therapy is to be useful,  it might 
best be used in patients who have a relatively intact T  cell 
repertoire containing cells that have not entirely committed 
to a fully differentiated  Th2 phenotype,  as well as  a suffi- 
cient number of naive CD4 + T  cells  to influence.  The ra- 
tionale to support the use oflL-12 to restore a deficient re- 
sponse  is  supported  by the  work  of Chemini  et  al.,  who 
demonstrated impaired  IL-12 production from PBMCs  of 
HIV-infected patients (5). With regard to enhancing an ex- 
isting response above a critical threshold,  it has been dem- 
onstrated  that  lL-12  treatment  protected  mice  infected 
with  Histoplasma capsulatum protects  from lethal  infection 
by enhancing an already existing response characterized by 
endogenous production oflL-12 and IFN-~/(31). 
In conclusion,  the  ability  of IL-12 to  enhance  CD8  T 
cell and NK cytolytic activity, as well as the properties dis- 
cussed  above,  make  it  an  interesting  candidate  for  treat- 
ment of HIV infection in combination with  antiretroviral 
therapy. Moreover, in cases where IL-2 production is lim- 
iting because of a  qualitative  or quantitative  T  cell defect, 
combination therapy with low (nontoxic)  doses of IL-2 or 
possibly IL-15 might enhance production of IFN-%  One 
final caveat is that while IL-12 treatment has been shown in 
several animal models to be important in regulating infec- 
tions  caused  by intracellular  microorganisms,  its  potential 
effect on HIV viral replication must be considered as well. 
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